Justin D. Lutz

1.2k citations

21 papers · 838 indexed · h-index 16

Pharmacology top 1%
Molecular Biology
Oncology
Infectious Diseases top 10%
Pediatrics, Perinatology and Child Health top 10%

Co-authors: Nina Isoherranen Anita Mathias Wendel L. Nelson Brian J. Kirby John Ling Alex Zelter Yoshiyuki Shirasaka Connie L. Davis
Topics: Pharmacogenetics and Drug Metabolism (12 papers)Drug Transport and Resistance Mechanisms (6 papers)Computational Drug Discovery Methods (4 papers)
Cited by: Pharmacology Biochemistry Infectious Diseases
Journals: Biochemical Pharmacology Clinical Pharmacology & Therapeutics Biochimica et Biophysica Acta (BBA) - General Subjects
Partner nations: United States United Kingdom Germany

In The Last Decade

Justin D. Lutz

21 papers receiving 818 citations

Peers

Countries citing papers authored by Justin D. Lutz

Since Specialization

Citations

This map shows the geographic impact of Justin D. Lutz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justin D. Lutz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justin D. Lutz more than expected).

Fields of papers citing papers by Justin D. Lutz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justin D. Lutz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justin D. Lutz. The network helps show where Justin D. Lutz may publish in the future.

Co-authorship network of co-authors of Justin D. Lutz

This figure shows the co-authorship network connecting the top 25 collaborators of Justin D. Lutz. A scholar is included among the top collaborators of Justin D. Lutz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justin D. Lutz. Justin D. Lutz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten 2025 ·Clinical Pharmacokinetics ·Donghong Xu,Justin D. Lutz,(unknown),Jianlin Li,(unknown),(unknown),Stephen B. Heitner,Stuart Kupfer,Polina German	2
2	Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor 2021 ·Clinical Pharmacokinetics ·Rita Humeniuk,Anita Mathias,Brian J. Kirby,Justin D. Lutz,Huyen Cao,Anu Osinusi,Darius Babusis,Danielle Porter,Xuelian Wei,John Ling,Y. Sunila Reddy,Polina German	93
3	Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications 2020 ·Clinical Pharmacology & Therapeutics ·Maciej J. Zamek‐Gliszczynski,Mitesh Patel,Xinning Yang,Justin D. Lutz,Xiaoyan Chu,Kim L. R. Brouwer,Yurong Lai,Caroline A. Lee,Sibylle Neuhoff,Mary F. Paine,Yuichi Sugiyama,Kunal S. Taskar,Aleksandra Galetin	39
4	Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition 2020 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Albert Liclican,(unknown),Weimei Xing,Gregg Czerwieniec,Bart Steiner,Ting Wang,Katherine M. Brendza,Justin D. Lutz,Kathleen S. Keegan,Adrian S. Ray,Brian E. Schultz,Roman Sakowicz,Joy Y. Feng	74
5	Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat 2020 ·Clinical Pharmacology & Therapeutics ·Brian J. Kirby,Justin D. Lutz,(unknown),Kimberly L. Garrison,Ann Qin,(unknown),Carine Beysen,Robert P. Myers,Brian P. Kearney,Anita Mathias	10
6	Safety, Pharmacokinetics and Pharmacodynamics of Selgantolimod, an Oral Toll-Like Receptor 8 Agonist: A Phase Ia Study in Healthy Subjects 2019 ·Antiviral Therapy ·(unknown),Justin D. Lutz,Audrey Lau,Anuj Gaggar,Ethan Grant,Adarsh Joshi,Richard L. Mackman,John Ling,Susanna K. Tan,Natarajan Ayithan,Stéphane Daffis,Jacky Woo,Peiwen Wu,Tina I. Lam,Simon P. Fletcher,Shyamasundaran Kottilil,Bhawna Poonia,Edward Gane,Anita Mathias,Polina German	12
7	Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine 2018 ·Clinical Pharmacology & Therapeutics ·Justin D. Lutz,Brian J. Kirby,Lu Wang,Qinghua Song,John Ling,Benedetta Massetto,Angela Worth,Brian P. Kearney,Anita Mathias	60
8	Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin 2018 ·Clinical Pharmacology & Therapeutics ·Justin D. Lutz,Brian J. Kirby,Lu Wang,Qinghua Song,John Ling,Benedetta Massetto,Angela Worth,Brian P. Kearney,Anita Mathias	63
9	Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator 2016 ·British Journal of Clinical Pharmacology ·(unknown),Xiaolu Tao,Li Zhu,(unknown),Justin D. Lutz,Eric Masson,Sean X. Zhang,Bishu Ganguly,(unknown),(unknown),Bindu Murthy	13
10	Detection of an Endogenous Urinary Biomarker Associated With Cyp2D6 Activity Using Global Metabolomics 2014 ·Pharmacogenomics ·(unknown),Laura M. Shireman,Richard P. Beyer,(unknown),Daniela Witten,Robin E. Pearce,Andrea Gaedigk,(unknown),Justin D. Lutz,Nina Isoherranen,Kenneth E. Thummel,Oliver Fiehn,J. Steven Leeder,Yvonne S. Lin	36
11	Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its Metabolite: Implications for Risk Assessment of Multiple Time-Dependent Inhibitor Systems 2013 ·Drug Metabolism and Disposition ·Justin D. Lutz,Brooke M. VandenBrink,(unknown),Wendel L. Nelson,Kent L. Kunze,Nina Isoherranen	22
12	Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions 2013 ·Drug Metabolism and Disposition ·Yoshiyuki Shirasaka,Jennifer E. Sager,Justin D. Lutz,Connie L. Davis,Nina Isoherranen	87
13	Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its Metabolite: Implications for Risk Assessment of Multiple Time- Dependent Inhibitor Systems s 2013 ·Justin D. Lutz,Brooke M. VandenBrink,(unknown),Wendel L. Nelson,Kent L. Kunze,Nina Isoherranen	1
14	In vitro-to-in vivopredictions of drug–drug interactions involving multiple reversible inhibitors 2012 ·Expert Opinion on Drug Metabolism & Toxicology ·Justin D. Lutz,Nina Isoherranen	17
15	Importance of Multi-P450 Inhibition in Drug–Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data 2012 ·Chemical Research in Toxicology ·Nina Isoherranen,Justin D. Lutz,(unknown),Houda Hachad,René H. Levy,Isabelle Ragueneau‐Majlessi	31
16	Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases 2011 ·Biochemical Pharmacology ·Ariel R. Topletz,(unknown),Alex Zelter,Justin D. Lutz,Suzanne Tay,Wendel L. Nelson,Nina Isoherranen	77
17	Prediction of Relative In Vivo Metabolite Exposure from In Vitro Data Using Two Model Drugs: Dextromethorphan and Omeprazole 2011 ·Drug Metabolism and Disposition ·Justin D. Lutz,Nina Isoherranen	45
18	Stereospecific Metabolism of Itraconazole by CYP3A4: Dioxolane Ring Scission of Azole Antifungals 2011 ·Drug Metabolism and Disposition ·(unknown),Wei Shi,Justin D. Lutz,Kent L. Kunze,Jun O. Liu,Wendel L. Nelson,Nina Isoherranen	23
19	Rationalization and prediction ofin vivometabolite exposures: the role of metabolite kinetics, clearance predictions andin vitroparameters 2010 ·Expert Opinion on Drug Metabolism & Toxicology ·Justin D. Lutz,Yasushi Fujioka,Nina Isoherranen	29
20	Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase 2008 ·Biochemical Pharmacology ·Justin D. Lutz,Vaishali Dixit,Catherine K. Yeung,Leslie J. Dickmann,Alex Zelter,(unknown),Wendel L. Nelson,Nina Isoherranen	76

About Justin D. Lutz

Justin D. Lutz is a scholar working on Pharmacology, Clinical Biochemistry and Pediatrics, Perinatology and Child Health, having authored 21 papers that have together received 838 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (12 papers), Drug Transport and Resistance Mechanisms (6 papers) and Computational Drug Discovery Methods (4 papers). The work is most often cited by research in Pharmacology (294 citations), Biochemistry (51 citations) and Infectious Diseases (154 citations). Justin D. Lutz has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Nina Isoherranen, Anita Mathias, Wendel L. Nelson, Brian J. Kirby, John Ling, Alex Zelter, Yoshiyuki Shirasaka, Connie L. Davis, Jennifer E. Sager and Brian P. Kearney. Their work appears in journals such as Biochemical Pharmacology, Clinical Pharmacology & Therapeutics and Biochimica et Biophysica Acta (BBA) - General Subjects.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact